|Small group of owners with great competence|
Nordvacc Läkemedel AB together with the research team and a few external investors are the principal owners of Intervacc AB.
Nordvacc was established in the beginning of the 1980s when the Swedish government decided to close down its production of vaccines. After several years as a development and production company Nordvacc was reorganised in 1991 and since then working with distribution, sales and clinical trials. Through the years Nordvacc has developed and commercialized 10 different conventional vaccines and sold more than 100 million vaccine doses.
Owners of Intervacc are also the researchers, Bengt Guss and Jan-Ingmar Flock, developing the vaccine. Other major shareholders are also Knutson Holdings, Lyftet Holdings and the Danish company Vepidan ApS. All together Intervacc has about 180 shareholders.